RxDoctor Payments Data

Jeffrey Dell, MD

Gynecology · Knoxville, TNNPI 1952355075

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (52.6%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. 5 manufacturers reported payments, led by Renovia Inc at 52.6% of the total. Among gynecology clinicians in TN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$8,127in general payments, 2019–2025

Across 23 payments — averaging $353.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Renovia Inc$4K
  • Medtronic$2K
  • Contura, Inc.$1K
  • Astellas Pharma US Inc$158
  • Caldera Medical, Inc$68

What the payments were for

  • Consulting fees$4,27553%
  • Speaking & faculty fees$2,00025%
  • Travel & lodging$7279%
  • Food & beverage$91111%
  • Education$1582%
  • Gifts$561%

General payments by program year

19
20
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Renovia Inc3$4,275
Medtronic(2 entities)8$2,381
Contura, Inc.8$1,245
Astellas Pharma US Inc2$158
Caldera Medical, Inc2$68

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,127 in reported general payments places this provider in the 95th percentile of 57 gynecology providers in Tennessee.

See all gynecology providers in Tennessee

Medicare billing

Part B allowed, 2024
$561,604
Medicare patients
702
Services billed
9,243

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron112$94,023
MyrbetriqMirabegron133$89,542
Solifenacin Succinate106$4,340
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst223$3,849
Estradiol69$3,786
Heparin SodiumHeparin Sodium,porcine22$2,949
Methenamine Hippurate42$2,432
Clobetasol Propionate42$2,073
Cefdinir52$1,989
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav123$1,989
Bethanechol Chloride57$1,391
Estradiol (Twice Weekly)Estradiol11$1,110
Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip56$903
Tetracycline Hcl17$643
Lidocaine Hcl21$630

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$158$89,542133 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 57 gynecology providers in Tennessee.

Other gynecology in Knoxville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →